Index RUT
P/E -
EPS (ttm) -5.45
Insider Own 3.28%
Shs Outstand 101.64M
Perf Week -0.71%
Market Cap 6.73B
Forward P/E -
EPS next Y -3.28
Insider Trans -6.45%
Shs Float 101.15M
Perf Month -9.28%
Income -526.24M
PEG -
EPS next Q -1.14
Inst Own 108.38%
Short Float 13.88%
Perf Quarter -20.81%
Sales 7.53M
P/S 893.58
EPS this Y 18.23%
Inst Trans -1.40%
Short Ratio 7.03
Perf Half Y 84.57%
Book/sh -3.80
P/B -
EPS next Y 26.51%
ROA -57.23%
Short Interest 14.04M
Perf Year 72.45%
Cash/sh 5.88
P/C 10.94
EPS next 5Y 15.00%
ROE -
52W Range 25.98 - 110.25
Perf YTD -22.94%
Dividend Est. -
P/FCF -
EPS past 5Y -22.79%
ROI -154.11%
52W High -41.64%
Beta 0.81
Dividend TTM -
Quick Ratio 6.12
Sales past 5Y 12.30%
Gross Margin -82.78%
52W Low 147.65%
ATR (14) 2.74
Dividend Ex-Date -
Current Ratio 6.12
EPS Y/Y TTM -28.21%
Oper. Margin -6589.71%
RSI (14) 42.21
Volatility 3.18% 3.91%
Employees 423
Debt/Eq -
Sales Y/Y TTM -92.04%
Profit Margin -6988.63%
Recom 1.44
Target Price 96.06
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 4.77%
Payout -
Rel Volume 0.29
Prev Close 63.37
Sales Surprise -78.05%
EPS Surprise -43.97%
Sales Q/Q -14.56%
Earnings May 08 AMC
Avg Volume 2.00M
Price 64.34
SMA20 -5.78%
SMA50 -6.99%
SMA200 24.54%
Trades
Volume 576,673
Change 1.53%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-24-24 Downgrade
UBS
Buy → Neutral
$61 → $92
Jan-05-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$60 → $90
Nov-09-23 Initiated
Goldman
Buy
$50
Nov-07-23 Initiated
B. Riley Securities
Buy
$66
Aug-15-23 Initiated
SVB Securities
Outperform
$58
Feb-17-23 Initiated
BofA Securities
Neutral
$49
Dec-23-22 Reiterated
Needham
Buy
$60 → $58
Dec-20-22 Initiated
Truist
Buy
$60
Oct-11-22 Initiated
UBS
Buy
$80
Jan-28-22 Initiated
Goldman
Buy
$74
Dec-22-21 Initiated
Oppenheimer
Outperform
$55
Dec-10-21 Initiated
JP Morgan
Overweight
$58
Oct-07-21 Initiated
Jefferies
Buy
$75
Mar-12-21 Initiated
Wolfe Research
Outperform
$50
Feb-18-21 Initiated
Barclays
Overweight
$28
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$22 → $41
Oct-29-20 Initiated
Goldman
Neutral
$16
Jul-10-20 Initiated
Raymond James
Strong Buy
$39
May-05-20 Initiated
Mizuho
Buy
$31
Apr-09-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$25
Show Previous Ratings
Today 04:00PM
May-01-24 10:01AM
Apr-29-24 04:00PM
Apr-26-24 04:44PM
06:00AM
04:00PM
Loading…
Apr-24-24 04:00PM
Apr-10-24 09:27AM
07:30AM
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
08:50AM
Loading…
Mar-17-24 08:50AM
Mar-13-24 02:25PM
Mar-12-24 06:46AM
(Thomson Reuters StreetEvents)
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
(FierceBiotech.com) -9.75%
10:22AM
07:30AM
Feb-27-24 05:10PM
04:42PM
04:17PM
(Associated Press Finance)
04:00PM
Feb-13-24 04:00PM
12:38AM
Loading…
Feb-12-24 12:38AM
Feb-09-24 10:01AM
(Investor's Business Daily)
Feb-08-24 09:10AM
Feb-06-24 04:00PM
Feb-05-24 05:30PM
(The Wall Street Journal)
Jan-29-24 07:30AM
Jan-25-24 07:30AM
Jan-18-24 01:00PM
Jan-12-24 04:40PM
02:47PM
01:07PM
05:27AM
Jan-11-24 04:22PM
04:05PM
12:58PM
(The Wall Street Journal)
12:54PM
12:47PM
(The Wall Street Journal)
12:30PM
Jan-10-24 01:04PM
Jan-09-24 01:17PM
Jan-08-24 05:14PM
(The Wall Street Journal) +15.29%
04:42PM
(Investor's Business Daily)
02:12PM
(Investor's Business Daily)
01:11PM
(The Wall Street Journal)
01:05PM
Jan-03-24 04:00PM
06:45AM
Jan-02-24 04:00PM
Dec-29-23 01:01PM
Dec-28-23 03:09PM
(Investor's Business Daily)
02:43PM
09:44AM
Dec-27-23 05:26PM
(Yahoo Finance Video) +82.54%
03:52PM
01:59PM
01:00PM
12:21PM
(Associated Press Finance)
09:41AM
08:34AM
07:39AM
07:32AM
07:30AM
Dec-26-23 04:00PM
Dec-15-23 10:22AM
Dec-07-23 07:30AM
Dec-01-23 04:00PM
Nov-29-23 04:00PM
Nov-10-23 03:04PM
Nov-04-23 12:16PM
Nov-03-23 04:00PM
11:43AM
(Thomson Reuters StreetEvents)
11:20AM
Nov-02-23 06:59PM
05:25PM
04:24PM
(Associated Press Finance)
04:00PM
09:55AM
Nov-01-23 04:00PM
Oct-31-23 02:24PM
12:43PM
Oct-26-23 09:08PM
Oct-23-23 04:00PM
Oct-19-23 07:30AM
Oct-09-23 07:53AM
Oct-06-23 12:45PM
Oct-05-23 04:00PM
Oct-03-23 04:00PM
Oct-02-23 04:00PM
Sep-28-23 07:30AM
Sep-15-23 01:05AM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HENDERSON JOHN T Director Apr 25 '24 Sale 64.54 10,562 681,671 32,070 Apr 25 06:54 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Option Exercise 6.67 28,605 190,795 171,172 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Sale 74.31 32,605 2,422,918 138,567 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Option Exercise 6.67 28,604 190,789 167,577 Mar 05 04:05 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Sale 67.56 32,604 2,202,606 138,973 Mar 05 04:05 PM HENDERSON JOHN T Director Feb 14 '24 Option Exercise 4.44 5,000 22,200 47,632 Feb 14 04:04 PM HENDERSON JOHN T Director Feb 14 '24 Sale 76.48 5,000 382,400 42,632 Feb 14 04:04 PM Blum Robert I President & CEO Feb 13 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 13 04:01 PM Blum Robert I President & CEO Feb 13 '24 Sale 76.85 12,500 960,625 441,797 Feb 13 04:01 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Option Exercise 6.67 28,605 190,795 175,578 Feb 06 04:43 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Sale 79.30 32,605 2,585,496 142,973 Feb 06 04:43 PM Blum Robert I President & CEO Jan 31 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 02 04:41 PM Blum Robert I President & CEO Jan 31 '24 Sale 79.57 12,500 994,625 441,797 Feb 02 04:41 PM Blum Robert I President & CEO Jan 19 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 22 05:19 PM Blum Robert I President & CEO Jan 19 '24 Sale 81.42 12,500 1,017,750 441,797 Jan 22 05:19 PM HENDERSON JOHN T Director Jan 12 '24 Option Exercise 4.44 5,000 22,200 47,632 Jan 12 05:20 PM HENDERSON JOHN T Director Jan 12 '24 Sale 85.14 5,000 425,700 42,632 Jan 12 05:20 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Option Exercise 7.96 11,678 92,957 162,651 Jan 04 04:36 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Sale 86.98 15,678 1,363,712 146,973 Jan 04 04:36 PM Blum Robert I President & CEO Jan 02 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 02 05:55 PM Blum Robert I President & CEO Jan 02 '24 Sale 85.08 12,500 1,063,500 441,797 Jan 02 05:55 PM WIERENGA WENDALL Director Dec 27 '23 Option Exercise 4.44 10,000 44,400 23,653 Dec 27 04:11 PM WIERENGA WENDALL Director Dec 27 '23 Sale 73.60 10,000 736,000 18,653 Dec 27 04:11 PM HENDERSON JOHN T Director Dec 18 '23 Option Exercise 6.72 13,020 87,494 44,838 Dec 19 04:12 PM Blum Robert I President & CEO Dec 18 '23 Option Exercise 6.67 12,500 83,375 454,297 Dec 19 04:13 PM Blum Robert I President & CEO Dec 18 '23 Sale 36.95 12,500 461,875 441,797 Dec 19 04:13 PM HENDERSON JOHN T Director Dec 18 '23 Sale 36.34 2,458 89,324 42,380 Dec 19 04:12 PM Blum Robert I President & CEO Nov 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Dec 01 04:15 PM Blum Robert I President & CEO Nov 30 '23 Sale 32.99 12,500 412,375 441,417 Dec 01 04:15 PM Blum Robert I President & CEO Nov 15 '23 Option Exercise 6.67 12,500 83,375 453,917 Nov 15 05:22 PM Blum Robert I President & CEO Nov 15 '23 Sale 34.57 12,500 432,125 441,417 Nov 15 05:22 PM Malik Fady Ibraham EVP Research & Development Nov 09 '23 Sale 35.40 2,500 88,500 150,664 Nov 09 04:35 PM Blum Robert I President & CEO Oct 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 30 04:02 PM Blum Robert I President & CEO Oct 30 '23 Sale 32.17 12,500 402,125 441,417 Oct 30 04:02 PM Blum Robert I President & CEO Oct 16 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 16 05:57 PM Blum Robert I President & CEO Oct 16 '23 Sale 33.70 12,500 421,250 441,417 Oct 16 05:57 PM Malik Fady Ibraham EVP Research & Development Oct 12 '23 Sale 35.89 2,500 89,725 153,164 Oct 12 06:39 PM Blum Robert I President & CEO Oct 06 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 06 04:52 PM Blum Robert I President & CEO Oct 06 '23 Sale 30.00 12,500 375,000 441,417 Oct 06 04:52 PM Malik Fady Ibraham EVP Research & Development Sep 14 '23 Sale 34.86 2,500 87,150 155,664 Sep 14 04:09 PM Blum Robert I President & CEO Sep 13 '23 Option Exercise 6.67 12,500 83,375 453,917 Sep 13 04:09 PM Blum Robert I President & CEO Sep 13 '23 Sale 34.90 12,500 436,206 441,417 Sep 13 04:09 PM Blum Robert I President & CEO Aug 25 '23 Option Exercise 7.70 12,500 96,275 453,917 Aug 28 06:45 PM Blum Robert I President & CEO Aug 25 '23 Sale 33.99 12,500 424,875 441,417 Aug 28 06:45 PM WIERENGA WENDALL Director Aug 21 '23 Option Exercise 6.72 6,020 40,454 24,225 Aug 21 04:01 PM WIERENGA WENDALL Director Aug 21 '23 Sale 32.02 6,020 192,760 18,205 Aug 21 04:01 PM Blum Robert I President & CEO Aug 11 '23 Option Exercise 9.54 12,500 119,287 453,125 Aug 11 04:18 PM Blum Robert I President & CEO Aug 11 '23 Sale 32.37 12,500 404,589 441,417 Aug 11 04:18 PM Malik Fady Ibraham EVP Research & Development Aug 10 '23 Sale 31.70 2,500 79,250 158,164 Aug 10 04:14 PM Blum Robert I President & CEO Aug 01 '23 Option Exercise 9.65 12,500 120,625 452,108 Aug 01 04:57 PM Blum Robert I President & CEO Aug 01 '23 Sale 32.63 12,500 407,856 441,417 Aug 01 04:57 PM Blum Robert I President & CEO Jul 13 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 13 04:10 PM Blum Robert I President & CEO Jul 13 '23 Sale 35.28 12,500 440,940 441,417 Jul 13 04:10 PM Malik Fady Ibraham EVP Research & Development Jul 13 '23 Sale 35.37 2,500 88,425 160,664 Jul 13 04:09 PM Bhanji Muna Director Jul 07 '23 Sale 34.12 2,000 68,235 14,031 Jul 07 04:17 PM Blum Robert I President & CEO Jul 03 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 05 04:18 PM Blum Robert I President & CEO Jul 03 '23 Sale 32.60 12,500 407,500 441,417 Jul 05 04:18 PM Blum Robert I President & CEO Jun 12 '23 Option Exercise 9.65 12,500 120,625 453,917 Jun 12 05:49 PM Blum Robert I President & CEO Jun 12 '23 Sale 37.06 12,500 463,250 441,417 Jun 12 05:49 PM Malik Fady Ibraham EVP Research & Development Jun 08 '23 Sale 38.07 2,500 95,175 163,164 Jun 08 04:31 PM Blum Robert I President & CEO May 31 '23 Option Exercise 9.65 12,500 120,625 453,558 Jun 01 05:06 PM Blum Robert I President & CEO May 31 '23 Sale 37.67 12,500 470,875 441,058 Jun 01 05:06 PM Blum Robert I President & CEO May 16 '23 Option Exercise 9.65 12,500 120,625 453,558 May 16 04:33 PM Blum Robert I President & CEO May 16 '23 Sale 37.41 12,500 467,625 441,058 May 16 04:33 PM HENDERSON JOHN T Director May 15 '23 Option Exercise 6.78 4,166 28,245 29,586 May 15 04:07 PM HENDERSON JOHN T Director May 15 '23 Sale 37.77 4,166 157,350 25,420 May 15 04:07 PM Malik Fady Ibraham EVP Research & Development May 11 '23 Sale 39.50 1,787 70,586 165,396 May 11 05:26 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Option Exercise 7.96 7,000 55,720 174,183 May 03 04:46 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Sale 40.00 7,000 280,000 167,183 May 03 04:46 PM
Index RUT
P/E -
EPS (ttm) -3.20
Insider Own 4.29%
Shs Outstand 89.90M
Perf Week 6.90%
Market Cap 1.73B
Forward P/E 77.14
EPS next Y 0.25
Insider Trans -1.53%
Shs Float 86.02M
Perf Month -5.32%
Income -263.30M
PEG -
EPS next Q -0.10
Inst Own 101.96%
Short Float 6.39%
Perf Quarter -11.06%
Sales 753.20M
P/S 2.29
EPS this Y 109.26%
Inst Trans 1.69%
Short Ratio 8.58
Perf Half Y 23.36%
Book/sh 8.71
P/B 2.21
EPS next Y 896.67%
ROA -20.54%
Short Interest 5.50M
Perf Year -9.60%
Cash/sh 1.58
P/C 12.16
EPS next 5Y -8.20%
ROE -31.55%
52W Range 13.82 - 24.21
Perf YTD 0.42%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -28.65%
52W High -20.61%
Beta 1.94
Dividend TTM -
Quick Ratio 1.87
Sales past 5Y 4.63%
Gross Margin 62.96%
52W Low 39.07%
ATR (14) 0.83
Dividend Ex-Date -
Current Ratio 2.01
EPS Y/Y TTM -131.34%
Oper. Margin -19.33%
RSI (14) 45.11
Volatility 5.27% 3.84%
Employees 2700
Debt/Eq 0.19
Sales Y/Y TTM 11.03%
Profit Margin -34.96%
Recom 2.85
Target Price 23.33
Option/Short Yes / Yes
LT Debt/Eq 0.17
EPS Q/Q 30.17%
Payout -
Rel Volume 0.77
Prev Close 19.47
Sales Surprise 0.92%
EPS Surprise 181.69%
Sales Q/Q 10.57%
Earnings Feb 27 AMC
Avg Volume 641.08K
Price 19.22
SMA20 -0.54%
SMA50 -8.04%
SMA200 0.61%
Trades
Volume 493,886
Change -1.28%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-23 Resumed
Piper Sandler
Neutral
$23
Dec-19-23 Initiated
Wells Fargo
Equal Weight
$20
Dec-14-23 Initiated
Guggenheim
Buy
$23
Dec-13-23 Initiated
Wolfe Research
Outperform
$28
Jul-05-23 Resumed
JP Morgan
Underweight
$18
May-23-23 Upgrade
Goldman
Sell → Buy
$18 → $25
Jan-18-23 Upgrade
Raymond James
Mkt Perform → Outperform
$25
Oct-06-22 Initiated
Stephens
Equal-Weight
$22
Oct-15-21 Resumed
Cowen
Market Perform
$33
Jun-15-21 Initiated
Raymond James
Mkt Perform
Jun-03-21 Initiated
Goldman
Sell
$25
Sep-26-19 Downgrade
BofA/Merrill
Neutral → Underperform
$30 → $28
Aug-14-19 Downgrade
Piper Jaffray
Overweight → Neutral
$45 → $40
Aug-02-19 Upgrade
BofA/Merrill
Underperform → Neutral
Aug-01-19 Upgrade
Barclays
Underweight → Equal Weight
$18 → $40
Jul-29-19 Downgrade
Needham
Strong Buy → Hold
Jul-09-19 Downgrade
Cowen
Outperform → Market Perform
Mar-12-19 Reiterated
Needham
Strong Buy
$37 → $41
Jan-03-19 Initiated
Needham
Strong Buy
$36
Nov-30-18 Upgrade
Goldman
Sell → Neutral
Show Previous Ratings
Apr-30-24 04:05PM
Apr-24-24 10:01AM
Apr-17-24 08:00AM
Apr-16-24 09:15AM
Apr-11-24 10:00AM
09:10AM
Loading…
Apr-09-24 09:10AM
08:00AM
Mar-28-24 11:30AM
Mar-27-24 07:51AM
Mar-21-24 09:40PM
Mar-20-24 04:05PM
Mar-01-24 09:41AM
Feb-28-24 02:45PM
(Morningstar Research) -8.04%
11:24AM
(Thomson Reuters StreetEvents)
10:24AM
07:50AM
Loading…
07:50AM
Feb-27-24 07:00PM
06:30PM
04:42PM
04:05PM
09:15AM
Feb-26-24 09:16AM
Feb-21-24 04:05PM
Feb-16-24 07:05AM
Feb-15-24 04:05PM
Feb-01-24 09:25AM
Jan-30-24 05:00PM
Jan-25-24 07:05PM
Jan-22-24 08:55AM
Jan-18-24 06:10PM
04:05PM
Loading…
Jan-09-24 04:05PM
Jan-04-24 11:10AM
Jan-03-24 04:05PM
Dec-21-23 03:05PM
09:17AM
08:30AM
Dec-20-23 08:00AM
Dec-14-23 08:22AM
Dec-06-23 11:30AM
Nov-21-23 10:54AM
Nov-20-23 04:05PM
11:18AM
Nov-16-23 04:05PM
Nov-09-23 07:00AM
Nov-08-23 09:20PM
04:10PM
Nov-07-23 02:30PM
(Morningstar Research) +8.69%
10:24AM
10:09AM
Nov-06-23 07:00PM
04:59PM
04:36PM
(Associated Press Finance)
04:05PM
Nov-04-23 03:02AM
Nov-03-23 07:04PM
(Morningstar Research) +6.51%
Nov-01-23 09:00AM
Oct-31-23 04:05PM
Oct-30-23 03:46PM
Oct-26-23 08:00AM
Oct-20-23 10:31AM
Oct-09-23 06:56PM
Sep-29-23 11:44AM
Sep-28-23 04:59PM
07:00AM
Sep-22-23 11:51AM
Sep-20-23 07:42AM
Sep-19-23 09:00AM
07:00AM
Sep-18-23 08:00AM
Sep-12-23 11:41AM
Sep-08-23 11:49AM
Sep-07-23 11:30AM
Sep-06-23 04:05PM
07:00AM
Sep-05-23 08:00AM
Aug-23-23 09:48AM
Aug-22-23 09:00AM
Aug-17-23 04:05PM
Aug-16-23 08:36AM
Aug-15-23 07:05AM
Aug-11-23 10:34AM
Aug-08-23 04:05PM
Aug-07-23 04:05PM
12:12PM
Aug-05-23 08:29AM
Aug-04-23 09:00PM
07:08PM
07:09AM
(Thomson Reuters StreetEvents)
Aug-03-23 06:35PM
04:05PM
Jul-27-23 04:05PM
Jul-24-23 08:00AM
Jul-06-23 08:30AM
Jun-30-23 11:16AM
Jun-28-23 09:32AM
Jun-21-23 08:00PM
Jun-17-23 07:00AM
Jun-13-23 08:16AM
Jun-12-23 08:00AM
Jun-07-23 04:05PM
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Riggsbee Richard Bryan Chief Financial Officer Dec 01 '23 Sale 19.09 30,000 572,835 291,812 Dec 05 04:19 PM Riggsbee Richard Bryan Chief Financial Officer Nov 01 '23 Sale 15.69 30,000 470,622 321,812 Nov 03 05:12 PM SPIEGELMAN DANIEL K Director Jun 02 '23 Sale 23.01 8,638 198,760 40,493 Jun 02 06:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite